All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Hemostatic Radiotherapy Represents Tool for Management of GI Bleeding in Advanced Cancer

April 18th 2023

Hemostatic radiation is a method of managing bleeding in patients with gastrointestinal cancers or GI metastases from other primary tumors; however, a multidisciplinary team is required to implement this method, according to Marnee M. Spierer, MD, MBA.

Cedars-Sinai Cancer Collaborates on a New Type of Clinical Trial

April 18th 2023

Investigators from Cedars-Sinai Cancer are collaborating on a streamlined clinical trial design in a study called Pragmatica-Lung.

IBI351 Demonstrates Early Antitumor Activity and Tolerability in KRAS G12C+ Advanced NSCLC

April 18th 2023

The recommended phase 2 dose of IBI351 monotherapy had favorable safety and encouraging efficacy signals when administered to patients with advanced KRAS G12C–mutated non–small cell lung cancer, according to updated data from a phase 1 dose-escalation study.

Lifirafenib/Mirdametinib Combination Is Safe and Tolerable in Advanced/Refractory Solid Tumors

April 18th 2023

Lifirafenib plus mirdametinib produced a tolerable safety profile and antitumor activity in patients with BRAF- or KRAS-mutant advanced or refractory solid tumors.

Novel KRAS G12C Inhibitor Shows Early Signs of Efficacy Across Solid Tumors, Pretreated NSCLC

April 17th 2023

LY3537982, an investigative KRAS G12C inhibitor, demonstrated clinical efficacy across patients with non–small cell lung cancer, colorectal cancer, and other solid tumors.

BGB-3245 Displays Early Antitumor Activity in Advanced/Refractory Solid Tumors With MAPK Pathway Mutations

April 17th 2023

The RAF dimer inhibitor BGB-3245 generated early efficacy signals with a tolerable safety profile in patients with advanced or refractory solid tumors harboring MAPK pathway mutations.

ALLO-316 Demonstrates Antitumor Activity in Advanced Clear Cell RCC

April 17th 2023

The allogeneic anti-CD70 CAR T-cell therapy ALLO-316 elicited signals of antitumor activity and showed a tolerable safety profile in patients with advanced or metastatic clear cell renal cell carcinoma.

African Ancestry Is Associated With Fewer Actionable Alterations in CRC

April 17th 2023

Patients with African ancestry with colorectal cancer have fewer actionable gene mutations than those with European ancestry, leading to fewer targeted treatment options in this population.

REGN5459 Delivers Dose-Dependent Responses in Relapsed/Refractory Myeloma

April 17th 2023

The BCMA- and CD3-directed bispecific antibody REGN5459 led to fast onset, deep, and dose-dependent responses sustained over time, with a high frequency of manageable low-grade cytokine release syndrome in patients with relapsed/refractory multiple myeloma.

Pembrolizumab Yields High Response Rates for Patients With Unresectable Metastatic Desmoplastic Melanoma

April 17th 2023

Patients with unresectable metastatic desmoplastic melanoma achieved high response rates when treated with single-agent pembrolizumab in the SWOG S1512 trial, according to data presented during the 2023 AACR Annual Meeting.

Selective CDK2 Inhibitor Undergoes Investigation in CCNE1-High Tumors

April 17th 2023

Preclinical data have demonstrated activity of a novel, small molecule CDK2 inhibitor INCB123667 in CDK2/cyclin E1 expressing cell lines prompting investigators to initiate a phase 1 study, and the agent may fill an unmet need for patients with cancers with primary or acquired CDK4/6 resistance.

FDA Accepts sBLA for Ide-cel in Triple-class Exposed Relapsed/Refractory Myeloma

April 17th 2023

The FDA has accepted a supplemental biologics license application seeking the approval of idecabtagene vicleucel for the treatment of adult patients with relapsed and refractory multiple myeloma who have received an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

Research Uncovers Alternate Mechanism for Producing Key Protein in Metastatic Prostate Cancer

April 17th 2023

In a new study in the journal Nature Cancer, Dana-Farber Cancer Institute scientists shed new light on the mechanism that raises and lowers PSMA expression in prostate cancer cells.

AFM13 Exhibits Efficacy in CD30+ Relapsed/Refractory PTCL

April 17th 2023

The investigational tetravalent bispecific antibody AFM13 displayed clinical efficacy in heavily pretreated patients with CD30-positive relapsed/refractory peripheral T-cell lymphoma.

Tafasitamab Plus Lenalidomide Has Continued Efficacy and Safety in R/R DLBCL

April 16th 2023

The combination of tafasitamab and lenalidomide followed by tafasitamab maintenance prolonged responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

Perioperative Durvalumab Plus Neoadjuvant Chemo Improves pCR, EFS in Resectable NSCLC

April 16th 2023

Perioperative durvalumab plus neoadjuvant platinum-based chemotherapy demonstrated a statistically significant improvement in pathologic complete response and event-free survival vs placebo plus chemotherapy in patients with resectable non–small cell lung cancer.

Adjuvant mRNA-4157 Plus Pembrolizumab Improves RFS in Resected High-Risk Melanoma

April 16th 2023

mRNA-4157 in combination with pembrolizumab improved recurrence-free survival compared with pembrolizumab alone when used as an adjuvant treatment in patients with resected high-risk melanoma, regardless of tumor mutational burden.

Pembrolizumab Plus Cisplatin/Gemcitabine Extends OS in Advanced Biliary Tract Cancer

April 16th 2023

Pembrolizumab plus cisplatin and gemcitabine produced a statistically significant and clinically meaningful improvement in overall survival vs placebo plus cisplatin and gemcitabine in previously untreated patients with advanced biliary tract cancer, according to data from the phase 3 KEYNOTE-966 trial.

Adjuvant Atezolizumab Plus Bevacizumab Significantly Improves RFS in High-risk HCC

April 16th 2023

Adjuvant treatment with the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) resulted in a statistically significant and clinically meaningful improvement in recurrence-free survival vs active surveillance in patients with a high risk of hepatocellular carcinoma recurrence following curative-intent resection or ablation.

MOUNTAINEER and DESTINY-CRC01 Trials Expand Second-Line Options for HER2+ mCRC

April 15th 2023

Alaa Muslimani, MD, discusses the significance of the phase 2 DESTINY-CRC01 and MOUNTAINEER-03 trials on HER2-positive metastatic colorectal cancer treatment in the second line, efforts to expand the use of these agents in earlier disease settings, and the need for more robust clinical data and larger investigations for this population.